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Background: The objective of this study was to evaluate the radiation dose and response in terms of local-regional
progression-free survival (LRPFS) and overall survival (OS) of patients with stage IV non-small cell lung cancer
(NSCLC) undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy.
Methods: In all, we enrolled 201 patients with stage IV NSCLC in this study and analyzed OS in 159 patients and
LRPFS in 120.
Results: The 1-, 2-, 3-, and 5-year OS rates were 46.2%, 19.5%, 11.7%, and 5.8%, respectively, the median survival
time being 12 months. The median survival times in differential treatment response of primary tumors were 19 of
complete response, 13 of partial response, 8 of stable disease, and 6 months of progressive disease, respectively
(P = 0.000). The 1-, 2-, 3-, and 5-year LRPFS rates of patients undergoing four to five cycles with doses ≥63 Gy and
<63 Gy were 77.4% and 32.6%, 36.2% and 21.7%, 27.2% and 0, and 15.9% and 0, respectively (P = 0.002). According
to multivariate analyses, four to five cycles of chemotherapy, gross tumor volume <175.00 cm3 and post-treatment
Karnofsky Performance Status score stable or increased by at least 10 units were independent prognostic factors for
better OS (P = 0.035, P = 0.008, and P = 0.000, respectively). Radiation dose to the primary tumor ≥63 Gy resulted in
better OS (P = 0.057) and LRPFS (P = 0.051), both findings being of borderline significance.
Conclusions: Treatment of IV NSCLC with joint administration of four to five cycles of chemotherapy and
three-dimensional radiotherapy may prolong survival, particularly in patients receiving ≥63 Gy radiotherapy,
with gross tumor volume <175.00 cm3 and post-treatment Karnofsky Performance Status score not lower than
pretreatment values.
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Approximately 30% to 40% of patients with non-small cell
lung cancer (NSCLC) have stage IV disease at the time of
initial diagnosis. Systemic chemotherapy is the standard
treatment option for these patients [1,2]. NSCLC patients
with epidermal growth factor receptor gene mutations
may also receive molecular targeted therapy, which pro-
longs progression-free survival (PFS) in 20%–30% of ad-
vanced cases [3-6]. Approximately 70% of patients still
require platinum-based combination chemotherapy; dif-
ferent third-generation chemotherapy regimens have
similar efficacy, indicating that the efficacy of chemo-
therapy has reached a plateau [7]. The efficacy of palliative
two-dimensional (2D) radiotherapy for treating stage IV
NSCLC patients with thoracic lesions has been systema-
tically reviewed; the reviewers concluded that there were
flaws in some aspects of the designs of the studies they
reviewed. Therefore, they questioned the validity of the
conclusions drawn in those studies [8]. Three-dimensional
(3D) radiotherapy is another treatment option for patients
with NSCLC [9]. The results of Radiation Therapy Onco-
logy Group 0617, which randomly assigned patients to
radiation doses of 60 Gy versus 74 concurrently with
carboplatin and paclitaxel, failed to show any benefit for
higher radiation dose in patients with locally advanced
NSCLC [10]. In contrast, the response rate and higher
dose correlated strongly with improved overall survival
(OS) and/or PFS in patients with locally advanced NSCLC
[11,12]. In advanced NSCLC, a higher dose correlated
with improved survival in the studies of Su et al. and
Lopez et al. [13,14]. The present study was designed to
evaluate the associations between local radiation dose,
local response, and survival in stage IV NSCLC patients
undergoing concurrent chemotherapy and thoracic 3D
radiotherapy.
Methods
Inclusion and exclusion criteria
This prospective study was performed with the approval
of the Institutional Review Board of the Affiliated Hospital
of Guiyang Medical College, and Guizhou Cancer Hos-
pital China and informed consent was obtained from all
patients. The inclusion criteria were as follows: 1) histo-
logically or cytologically confirmed NSCLC; 2) newly diag-
nosed stage IV disease according to the staging system of
the 2002 American Joint Committee on Cancer; 3) age
18–80 years with a Karnofsky Performance Status (KPS)
score ≥70; 4) limited metastatic disease (≤five sites); 5) no
contraindications to radiotherapy and chemotherapy;
6) underwent at least two cycles of chemotherapy and re-
ceived radiation at doses ≥36 Gy; and 7) adequate bone
marrow, liver, and renal function (defined as neutrophil
count ≥1.5 × 109/L, platelet count 80 × 109/L, hemoglobin
concentration ≥80 g/L, aspartate aminotransferase andalanine aminotransferase concentrations ≤2× the upper
limit of the institutional normal range, total bilirubin
≤1.25× the upper limit of the institutional normal range,
and creatinine concentration ≤120 μmol/L). The exclusion
criteria were as follows: 1) previous thoracic surgery,
radiotherapy, or chemotherapy; 2) malignant pleural or
pericardial effusion; 3) pregnancy or lactation; and 4) pre-
vious malignancy or other concomitant malignant disease.
Pre- and post-treatment assessment
Means of pretreatment assessment comprised physical
examination, hematologic and biochemical profiles, fiber-
optic bronchoscopy, contrast-enhanced computed tomo-
graphy (CT) scanning of the chest and abdominal region,
plain or contrast-enhanced magnetic resonance imaging
(MRI) of the head, and bone scintigraphy. Additional
investigations were performed if indicated. All the same
assessments, except for fiberoptic bronchoscopy and bone
scintigraphy, were also performed after therapy.
General clinical data
In all, 201 patients diagnosed with stage IV NSCLC bet-
ween January 2003 and July 2010 were enrolled in this
study. Nineteen patients underwent only one cycle of
chemotherapy, 10 received <36 Gy and 13 cases refused
post-treatment evaluation by imaging. These 42 cases
were omitted from the analyses. Combination chemothe-
rapy and radiation were administered to intrathoracic pri-
mary tumors in the remaining 159 patients, 119 of whom
were male and 40 female. The patients were aged 30–80
years (median age 59 years). The median gross tumor
volume (GTV) was 175.00 cm3 (16.55–892.00 cm3). The
median number of cycles of chemotherapy was 4 (2–5
cycles), and the median dose to the planning target vo-
lume was 63 Gy (36–72 Gy). Post-treatment progression
of the primary tumor occurred in 11 patients. Twenty-
eight patients participated in post-treatment follow-up via
telephone but refused re-examination by imaging; thus,
120 were assessed for local-regional progression-free sur-
vival (LRPFS). These patients’ clinical characteristics are
listed in Table 1. Significantly more patients received four
to five cycles with radiation doses ≥ 63 Gy than <63 Gy.
Metastases were in bone, lung, brain, liver, renal capsule
and other sites. The most common sites of metastatic dis-
ease were bone (52.2%), lung (36.5%), and brain (22.6%).
Metastases were detected in only one site in 98 cases
(61.6%), in two sites in 45 cases (28.3%), in three sites in
12 cases, four sites in three cases, and five sites in one
case.
Chemotherapy protocol
Platinum-based doublets chemotherapy was adminis-
tered according to the following regimens: 80 mg/m2
cisplatin (C) or carboplatin (Cb; 6 AUC) intravenously
Table 1 Clinical characteristics of patients (n = 120) in
whom local-regional progression-free survival was
assessed
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(D) on day 1, and 25 mg/m2 vinorelbine (V) on days 1 and
8 every 21–28 days during thoracic radiotherapy. Concur-
rent thoracic radiation was given within 1 week of starting
chemotherapy. After completion of thoracic radiotherapy,
patients with a response or stable disease continued
chemotherapy for up to four to six cycles, whereas
second-line therapy was substituted in patients withprogressive disease or unacceptable toxicity. PC or PCb
combination chemotherapy was administered to 40.3% of
patients (64/159), DC or DCb to 53.4% (85/159), and VC
to 6.3% (10/159). Thirty-one, 41, 83, and four patients
underwent two, three, four, and five cycles of chemo-
therapy, respectively. In all, 537 cycles were administered.
Radiotherapy protocol
The treatment was planned using ADAC Pinnacle3 radi-
ation treatment planning software (version 7.4f). The
GTV encompassed both the primary lung lesion and any
hilar and mediastinal lymph nodes that were visible on the
treatment planning CT scan. The GTV plus a margin of
15 mm was defined as the planning target volume, the
area covered by at least a 90% isodose surface. The V20
(percentage of total lung volume receiving ≥20 Gy), maxi-
mum point dose to the spinal cord and mean esophageal
dose were required to be ≤32%, 50 Gy and ≤35 Gy,
respectively, in each individual treatment plan. Patients
received late-course accelerated hyperfractionated radio-
therapy to the thoracic primary site using 3D-conformal
or intensity-modulated radiation therapy. The first course
of radiotherapy was given in two Gy fractions for 5 days a
week to a total dose of 36–40 Gy, whereas late-course
accelerated hyperfractionated radiotherapy was delivered
in two fractions of 1.5 Gy each with an interval of 6–8 h
each day. The protocol required delivery of a prescription
dose of 60–70 Gy to patients; individuals who did not to-
lerate this were to receive ≥36 Gy. Provided radiation
doses to normal tissue were acceptable, the radiation dose
to the primary thoracic tumor could be escalated to
72 Gy. Sixty-seven patients received <63 Gy and 92 ≥
63 Gy (70 received 63 Gy and 22 received 63–72 Gy).
Metastatic lesions were treated with 3D-conformal radi-
ation therapy or 2D hypofractionated radiotherapy. In all,
98 patients received radiotherapy concurrently or sequen-
tially with chemotherapy for metastatic lesions in 3–10 Gy
daily fractions to a total dose of 20–60 Gy.
Evaluation of therapeutic efficacy
The responses of the primary tumors, including complete
response (CR), partial response (PR), stable disease (SD),
and progressive disease (PD), were evaluated according to
the World Health Organization response criteria. LRPFS
was defined as the length of time between the start of
treatment and either progression of the primary tumor or
death. A comprehensive evaluation of both the primary
tumor and distant metastases was performed 1 month
after completion of chemoradiotherapy treatment. For pri-
mary tumors and metastatic lesions other than those in
bone, response rate was defined as CR or PR. However,
for patients with bone metastases, SD (i.e. no evidence of
PD) of bone metastases was also regarded as a response.
Nonresponse of primary tumors was defined as larger
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or development of new metastatic lesions.
Follow-up and statistical analyses
After completion of treatment, the patients underwent
contrast-enhanced CT scanning of the chest and abdom-
inal region and MRI of the head every 3 months for 2 years,
and every 6 months thereafter. Bone scintigraphy was per-
formed every 6 months for 2 years, and every 12 months
thereafter. All statistical analyses were performed using the
Statistical Package for Social Sciences version 13.0 (SPSS;
Chicago, IL, USA). The significance of differences in pro-
portions was assessed with the χ2 test. Kaplan–Meier ana-
lyses were performed to estimate LRPFS and OS and the
log-rank test to compare the survival curves. The Cox pro-
portional hazards model was used to perform multivariate
analyses to assess the LRPFS and OS. Results were con-
sidered statistically significant when the two-tailed P value
was <0.05.
Results
Differential treatment response of primary tumors
Follow-up ended on 1 March 2013. Four patients were lost
to follow-up; the remaining 155 patients (97.5%) under-
went follow-up for 2–80 months (median 12 months).
One hundred and forty-five patients had died by the study
end-point, 34 (23.5%) from local progression, 26 (17.9%)
from local progression and distant metastases, and 85
(58.6%) from distant metastases alone. Ten patients were
still alive, their survival times being 34–80 months. The
1-, 2-, 3-, and 5-year OS rates of the 159 study patients
were 46.2%, 19.5%, 11.7%, and 5.8%, respectively; their me-
dian survival time (MST) was 12 (95% CI, 9.8–14.2)
months. Twelve/159 patients (7.5%) achieved CR, 66.0%
(105/159) PR, 19.5% (31/159) SD, and 6.9% (11/159) PD,
the MSTs being 19 (95% CI, 8.5–29.5), 13 (95% CI, 10.9–
15.1), 8 (95% CI, 6.4–9.6), and 6 (95% CI, 4.4–7.6) months,
respectively (χ2 = 24.330, P = 0.000). The 1-, 2-, 3-, and
5-year OS rates of patients with CR/PR and SD/PD were
54.4% and 23.8%, 22.3% and 11.9%, 13.4% and 7.1%, and
5.4% and 4.8%, respectively, their MSTs being 14 (95% CI,
11.9–16.1) and 7 (95% CI, 5.4–8.6) months, respectively




1 year 2 year 3 year 5 year
CR 11 63.6 42.4 31.8 31.8
PR 91 58.3 27.5 18.3 0
SD 18 50.0 35.7 26.8 26.8
CR 11 63.6 42.4 31.8 31.8
PR + SD 109 56.9 29.0 19.7 7.8Comparison of LRPFS according to treatment responses
of primary tumors
The median LRPFS of the 120 patients in whom it was
assessed was 16 months (95% CI, 12.5–19.5). The 1-, 2-,
3-, and 5-year LRPFS rates were 57.5%, 30.5%, 21.0%,
and 10.2%, respectively. The LRPFS of patients in CR
seemed to be longer than of those in PR and SD; how-
ever, these differences were not significant (Table 2).
LRPFS according to radiation doses to primary tumors
The 1-, 2-, 3-, and 5-year LRPFS rates of patients receiving
radiation doses of ≥63 Gy or <63 Gy were 67.3% and
38.2%, 33.5% and 25.1%, 25.3% and 12.5%, and 15.1% and
0, respectively, their MSTs being 18 (95% CI, 15.2–20.8)
and 10 (95% CI, 8.1–11.9) months, respectively (χ2 = 5.458,
P = 0.019) (Figure 1).
Assessment of LRPFS in patients who received concurrent
chemotherapy and various doses of radiation to primary
tumors
The 1-, 2-, 3-, and 5-year LRPFS rates of patients undergo-
ing four to five cycles with doses ≥63 Gy versus <63 Gy
were 77.4% and 32.6%, 36.2% and 21.7%, 27.2% and 0, and
15.9% and 0, respectively, their MSTs being 20 (95% CI,
16.5–23.5) and 9 (95% CI, 6.6–11.4) months, respectively
(χ2 = 9.217, P = 0.002) (Table 3). The difference between
patients undergoing two to three cycles with doses ≥63 Gy
versus <63 Gy (χ2 = 0.040, P = 0.842) was not significant.
Effect of various combined chemoradiotherapy regimens
on LRPFS and OS
One hundred and five cases achieved responses and 54
did not. The 1-, 2-, 3-, and 5-year OS rates of patients
who did and did not respond were 60.7% and 18.5%,
24.9% and 9.3%, 14.9% and 5.6%, and 6.1% and 3.7%, re-
spectively, their MSTs being 15 (95% CI, 12.9–17.1) and
7 (95% CI, 6.0–8.0) months, respectively (χ2 = 20.715,
P = 0.000). The 1-, 2-, 3-, and 5-year LRPFS rates of pa-
tients who received four to five cycles with doses ≥63 Gy
and two to three cycles with doses ≥63 Gy were 77.4%
and 43.5%, 36.2% and 26.1%, 27.2% and 19.6%, and
15.9% and 0, respectively, their MSTs being 20 (95% CI,












Figure 1 Comparison of local-regional progression-free survival according to radiation dose to primary tumors.
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5-year LRPFS rates of patients who received four to five
cycles with doses ≥63 Gy compared with other treat-
ment regimens (including two to three cycles with doses
≥63 Gy, two to three cycles with doses <63 Gy, and four
to five cycles with doses <63 Gy) were 77.4% and 40.5%,
36.2% and 25.4%, 27.2% and 15.8%, and 15.9% and 0, re-
spectively, their MSTs being 20 (95% CI, 16.5–23.5) and
10 (95% CI, 7.6–12.4) months, respectively (χ2 = 8.065,
P = 0.005) (Figure 2).
Cox regression analyses
According to multivariate analyses, patients who received
four to five cycles of chemotherapy (HR, 1.484; 95% CI,
1.028–2.144; P = 0.035), GTV <175.00 cm3 (HR, 1.747; 95%
CI, 1.153–2.646; P = 0.008) and post-treatment KPS score
stable or increased by at least 10 units (HR, 6.282; 95% CI,
3.568–11.058; P = 0.000) were independent predictors ofTable 3 Local-regional progression-free survival in 120 stage
Cycle Dose(Gy) No.
Survival rate (%)
1 year 2 year 3 year 5 yea
2-3
<63 23 41.7 27.8 20.9 0
≥63 23 43.5 26.1 19.6 0
4-5
<63 18 32.6 21.7 0 0
≥63 56 77.4 36.2 27.2 15.9better OS. Both N stage (HR, 1.636; 95% CI, 0.981–2.727;
P = 0.059) and the primary tumor radiation dose (HR,
1.433; 95% CI, 0.989–2.075; P = 0.057) were of borderline
significance with respect to OS. GTV <175.00 cm3 (HR,
2.321; 95% CI, 1.336–4.032; P = 0.003) and post-treatment
KPS score (HR, 8.038; 95% CI, 3.769–17.140; P = 0.000)
were independent predictors of LRPFS. The primary
tumor radiation dose was of only borderline significance
with respect to LRPFS (HR, 1.562; 95% CI, 0.999–2.443;
P = 0.051) (Table 4).
Discussion
In patients with stage IV NSCLC, four to six cycles of
platinum-based combination chemotherapy typically re-
sults in 1-year survival rates of approximately 30%–45%,
median time to progression of 3–5 months, and median
survival time of 8–10 months [1,7,15-17]. However, un-













Figure 2 Comparison of local-regional progression-free survival between patients who underwent four to five cycles of chemotherapy
concurrently with radiotherapy at doses of ≥63 Gy and patients who received other treatment regimens.
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tients [18]. Higginson et al. [19] performed a pooled ana-
lysis of 189 patients enrolled at a single institution. They
found that pulmonary symptoms, total volume of intra-
thoracic lesions, and bronchial/vascular compression all
influenced survival after first-line, platinum-based che-
motherapy. A subset of these patients could be studied to
determine whether early, planned palliative thoracic ra-
diation would be beneficial. Whether palliative 2D ra-
diotherapy for chest lesions prolongs patient survival isTable 4 Multivariate analysis: overall survival and local-region
Variable
p
Gender (Female vs. Male) 0.288
Age (years) (≥65 vs. <65) 0.297
Pathological type (Non-squamous vs. Squamous) 0.106
T stage (T3-T4 vs. T1-T2) 0.728
Distant metastatic lesions (No radiotherapy vs. Radiotherapy) 0.682
Intrathoracic primary tumors (No response vs. Response) 0.592
GTV (<175 cm3 vs. ≥175 cm3) 0.008
Post-treatment KPS (Decreased ≥10 vs. Stable or increased ≥10) 0.000
N stage (N2-N3vs. N0-N1) 0.059
Chemotherapy cycles (2–3 vs. 4–5) 0.035
Intrathoracic primary tumors radiation doses (<63Gy vs. ≥63Gy) 0.057unknown and debatable [20,21]. Several prospective cli-
nical trials have been reviewed and found to have had
flaws in the enrollment of patients undergoing radiother-
apy alone; these flaws likely skewed the interpretation of
the effects of radiotherapy [8]. Future research should
focus on testing multiple regimens of combined chemo-
therapy (typically four to six cycles) and 3D radiotherapy
for primary tumors with stage IV NSCLC patients. An
earlier retrospective study showed that patients with KPS
scores ≥90 who underwent stereotactic radiotherapy oral progression-free survival
OS LRPFS
HR 95% CI p HR 95% CI
0.802 0.534-1.205 0.278 0.753 0.450-1.258
0.817 0.558-1.195 0.248 0.760 0.477-1.211
1.364 0.936-1.988 0.494 1.184 0.729-1.924
1.067 0.740-1.540 0.702 1.097 0.684-1.759
1.083 0.740-1.584 0.652 1.118 0.689-1.812
1.124 0.733-1.724 0.581 1.188 0.644-2.190
1.747 1.153-2.646 0.003 2.321 1.336-4.032
6.282 3.568-11.058 0.000 8.038 3.769-17.140
1.636 0.981-2.727 0.234 1.438 0.790-2.615
1.484 1.028-2.144 0.128 1.431 0.903-2.268
1.433 0.989-2.075 0.051 1.562 0.999-2.443
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concurrently with radical chemoradiotherapy or surgery
for intrathoracic lesions had a significantly longer MST
and higher survival rates than those whose intrathoracic
lesions were not treated (P = 0.000) [22], indicating that
patients with few metastases may benefit from radical
therapy for intrathoracic lesions [14,18]. In this study, the
OS time of patients who responded to treatment was sig-
nificantly longer than of those who did not respond; the
LRPFS of patients with CR was 5 months longer than of
those with PR/SD. These data suggest that the survival of
patients with stage IV NSCLC may be improved by ad-
ministering local radiotherapy to their primary tumors.
An earlier prospective trial showed that a 30 Gy/10 frac-
tions radiotherapy schedule is better than a 16 Gy/2 frac-
tions schedule for palliative treatment of patients with
stage IV NSCLC [23]. A systematic review of 13 rando-
mized controlled trials of palliative thoracic radiotherapy
showed that metastases are the major factor resulting in
failure of treatment of stage IV NSCLC; the presence of
uncontrolled intrathoracic lesions also significantly affects
treatment failure. High dose (35 Gy10 BED) palliative tho-
racic radiotherapy reportedly improves the total symptom
score and 1-year overall survival compared with lower
dose radiotherapy. These data indicate that some patients
benefit from receiving local radiotherapy [24]. A system-
atic review has shown that increasing fractionation and
total radiation dose to primary tumors may prolong pa-
tient survival [25]. Thus, further prospective clinical trials
to evaluate the efficacy of modern 3D radiotherapy given
concurrently with combination chemotherapy for stage IV
NSCLC are warranted. A long-term study in which the ra-
diation dose was escalated found that increasing the dose
improved the control rate of local tumors in patients with
locally advanced NSCLC [12]. In our study, the LRPFS
rate of patients who received intrathoracic radiotherapy at
doses ≥63 Gy was significantly higher than that of patients
who received <63 Gy. Importantly, four to six cycles of
chemotherapy has a significantly greater effect on survival
than does two to three cycles of chemotherapy [26]. In the
current study, patients who received intrathoracic radi-
ation at doses ≥63 Gy underwent a median of four cycles
of chemotherapy, which was one more cycle than was
given to patients who received radiation at doses <63 Gy.
Whether the intensity of chemotherapy affects the out-
come remains unclear. Subset analysis showed that the
LRPFS rate of patients who underwent two to three cycles
of chemotherapy concurrently with radiation at doses
of ≥63 Gy was similar to that of patients who underwent
two to three cycles of chemotherapy concurrently with ra-
diation at doses of <63 Gy. In contrast, the LRPFS rate
was significantly higher in patients undergoing four to five
cycles of chemotherapy concurrently with radiotherapy at
doses of ≥63 Gy. These data are consistent with findingsfrom an earlier retrospective study of 78 consecutive pa-
tients with oligometastatic NSCLC. That study found that
patients who received at least 63 Gy of radiation to their
primary tumors had better OS, PFS, and local control rate
than those who received <63 Gy, suggesting that control-
ling metastases by chemotherapy is equivalent to achie-
ving local control with 3D radiotherapy in such patients
[14]. The most efficient therapeutic strategy for stage IV
NSCLC involves both control of the primary tumor and
treatment of metastatic lesions. In this study, the LRPFS
was longer in patients who received at least 63 Gy of ra-
diation to their primary tumors concurrently with four to
five cycles of chemotherapy than in those who underwent
other treatment regimens. Multivariate analysis showed
that four to five cycles of chemotherapy is a predictor of
better OS. A primary tumor radiation dose ≥63 Gy pro-
vided better OS and LRPFS, these findings being of bor-
derline significance. Thus, there is a trend for thoracic 3D
radiotherapy together with systemic chemotherapy to pro-
long survival of patients with stage IV NSCLC.
The prognosis of NSCLC patients is closely associated
with both pre-treatment [9] and post-treatment perfor-
mance status. In the present study, the patients whose
post-treatment KPS scores were stable or increased had
higher OS rates and longer LRPFS than patients whose
scores decreased. This suggests that post-treatment per-
formance status should be maintained or improved; thus,
overtreatment should be avoided when treating stage IV
NSCLC with integrated treatment regimens.
Conclusions
Four to five cycles of chemotherapy given concurrently
with 3D radiotherapy for intrathoracic tumors may pro-
long survival, particularly in patients who receive radio-
therapy at doses ≥63 Gy, GTV < 175.00 cm3 and whose
post-treatment KPS scores do not decrease.
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